ProQR Therapeutics N.V. Files 2024 Annual Report
Ticker: PRQR · Form: 20-F · Filed: Mar 13, 2025 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 20-F |
| Filed Date | Mar 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, financing, partnerships, clinical-trials
TL;DR
ProQR filed its 2024 20-F, showing progress and partnerships like the one with Eli Lilly.
AI Summary
ProQR Therapeutics N.V. filed its 20-F for the fiscal year ending December 31, 2024. The company reported on its ongoing clinical trials and various agreements, including a Share Purchase Agreement with Eli Lilly and Company on October 25, 2024. Financial details and operational updates are provided in the filing.
Why It Matters
This filing provides investors with a comprehensive overview of ProQR's financial health, strategic partnerships, and progress in its drug development pipeline for the past fiscal year.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, ProQR Therapeutics faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the 20-F filing.)
- 2025-03-13 — Filing Date (The date ProQR Therapeutics N.V. submitted its 20-F.)
- 2024-10-25 — Share Purchase Agreement Date (Date of the agreement with Eli Lilly and Company.)
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Filer of the 20-F report
- Eli Lilly and Company (company) — Party to a Share Purchase Agreement with ProQR
- Foundation Fighting Blindness (FFB) (company) — Party to a Clinical Support Agreement
- Pontifax Medison And Kreos Capital (company) — Involved in Convertible Debt Financing
- Rett Syndrome Research Trust (company) — Party to a Research and Development Agreement
- Theresa Heggie (person) — Mentioned in relation to compensation scenarios
- Alison Lawton (person) — Mentioned in relation to compensation scenarios
- R.k. Beukema (person) — Mentioned in relation to compensation scenarios
FAQ
What is the primary focus of ProQR Therapeutics N.V.'s research and development as detailed in the 20-F?
The filing indicates a focus on developing RNA therapeutics for rare inherited diseases, with specific mentions of Ultevursen and agreements related to genetic eye diseases and Rett Syndrome.
What was the nature of the agreement with Eli Lilly and Company on October 25, 2024?
The filing references a 'Share Purchase Agreement with Eli Lilly and Company' executed on October 25, 2024.
What types of financing arrangements are mentioned in the filing?
The filing mentions 'Convertible Debt Financing' involving Pontifax Medison and Kreos Capital, and details related to stock options and restricted stock units (RSUs).
Who are the key individuals mentioned in relation to compensation or executive roles?
Key individuals mentioned include Ms. Theresa Heggie, Ms. Alison Lawton, and Mr. R.k. Beukema, in the context of compensation scenarios and vesting schedules.
What is the company's fiscal year end date?
ProQR Therapeutics N.V.'s fiscal year ends on December 31st, as indicated by the 2024-12-31 date associated with the filing.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on March 13, 2025 by Theresa Heggie regarding ProQR Therapeutics N.V. (PRQR).